EUVIMEDEUVIMED entdecken
Crossref

Curcusone D improves metabolic dysfunction associated steatotic liver disease via activation of the AMPK signaling

Danhua Yao, Shengke Wen, Qi Li, Yiming Jia, Lingfeng Wan, Min Qiu, Yuhua Huang, Wei Zhao

Molecular and Cellular Endocrinology · 2026-10 · 620 · 112847

DOI: 10.1016/j.mce.2026.112847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2026-10. Verfasst von Danhua Yao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. Hauptthemen laut MEDLINE: Signal Transduction, AMP-Activated Protein Kinases, Fatty Liver, Sesquiterpenes. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Provincial Science and Technology Support Program, School of Medicine, Shanghai Jiao Tong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide with limited effective clinical treatments. Previous high-throughput drug screening identified Curcusone D as a promising candidate for MASLD treatment. This study aimed to validate its therapeutic effects and underlying molecular mechanism. In vivo efficacy was evaluated in high-fat and high-cholesterol (HFHC) diet-fed mice, while in vitro hepatocyte models were used for mechanistic verification. The results demonstrated that Curcusone D significantly improved liver function, reduced serum pro-inflammatory cytokines, and suppressed hepatic inflammation and fibrosis in MASLD mice. It also markedly reversed excessive lipid accumulation and inhibited inflammatory responses in hepatocytes. Mechanistically, Curcusone D specifically activated the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway. Pharmacological inhibition of AMPK fully abolished the protective effects of Curcusone D against HFHC-induced hepatic steatosis, insulin resistance, inflammation and fibrosis. In conclusion, Curcusone D ameliorates MASLD progression via AMPK pathway activation, serving as a novel and druggable natural candidate for future MASLD clinical therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionAMP-Activated Protein KinasesFatty LiverSesquiterpenesAnimalsMice, Inbred C57BLMaleDiet, High-FatMiceHepatocytesLiverCytokinesInflammation

Stichwörter der Autor:innen

AMPKCurcusone DInflammationMetabolic dysfunction associated steatotic liver disease

Substanzen

AMP-Activated Protein KinasesSesquiterpenesCytokines

Autor:innen und Institutionen

  • Department of General Surgery, The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
  • School of Laboratory Medicine/Clinical IVD Joint Research Center of Chengdu Medical College-Maccura Biotechnology, Chengdu Medical College, Chengdu, 610500, China.
  • School of Clinical Medicine, Chengdu Medical College, Chengdu, 610500, China.
  • Fatty Liver Disease Center of Integrated Chinese and Western Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210600, China.
  • School of Laboratory Medicine/Clinical IVD Joint Research Center of Chengdu Medical College-Maccura Biotechnology, Chengdu Medical College, Chengdu, 610500, China. Electronic address: qiumin0227@163.com.
  • Department of General Surgery, The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. Electronic address: huangyuhua_1991@126.com.

Förderung

  • National Natural Science Foundation of China
  • Sichuan Provincial Science and Technology Support Program
  • School of Medicine, Shanghai Jiao Tong University
  • Chengdu Municipal Science and Technology Program

Zitieren

APA

Yao, D., Wen, S., Li, Q., Jia, Y., Wan, L., Qiu, M., Huang, Y., & Zhao, W. (2026). Curcusone D improves metabolic dysfunction associated steatotic liver disease via activation of the AMPK signaling. Molecular and Cellular Endocrinology, 620, 112847. https://doi.org/10.1016/j.mce.2026.112847

Vancouver

Yao D, Wen S, Li Q, Jia Y, Wan L, Qiu M, et al. Curcusone D improves metabolic dysfunction associated steatotic liver disease via activation of the AMPK signaling. Molecular and Cellular Endocrinology. 2026;620:112847. doi:10.1016/j.mce.2026.112847

BibTeX
@article{Yao2026,
  author = {Yao, Danhua and Wen, Shengke and Li, Qi and Jia, Yiming and Wan, Lingfeng and Qiu, Min and Huang, Yuhua and Zhao, Wei},
  title = {Curcusone D improves metabolic dysfunction associated steatotic liver disease via activation of the AMPK signaling},
  journal = {Molecular and Cellular Endocrinology},
  year = {2026},
  volume = {620},
  pages = {112847},
  doi = {10.1016/j.mce.2026.112847}
}
Kostenlos starten →